Highlights from the Annual Report UK Renal Registry 2013 Annual Audit Meeting Dr Catriona Shaw Registrar, UK Renal Registry.

Slides:



Advertisements
Similar presentations
UK Renal Registry 17th Annual Report Figure 5.1. Trend in one year after 90 day incident patient survival by first modality, 2003–2012 cohorts (adjusted.
Advertisements

UK Renal Registry 16th Annual Report Figure Data completeness for key variables, stratified by first modality HD = haemodialysis; PD = peritoneal.
The future of haemodialysis in the UK RCP advanced medicine 2013 Cormac Breen Consultant Nephrologist Guy's and St Thomas' Hospitals London.
UK Renal Registry 17th Annual Report Figure Data completeness for key variables, stratified by first modality DOB = date of birth; PRD = primary.
UK Renal Registry 15th Annual Report Figure One year death rate per 1,000 patient years by UK country and age group for prevalent dialysis.
UK Renal Registry 15th Annual Report Figure 8.1. Age and gender of PD patients submitted to audit.
UK Renal Registry 16th Annual Report Figure 5.1. Flow chart showing number of patients included in the various analyses.
An update from The UK Renal Registry Dr Fergus Caskey Medical Director, UK Renal Registry Annual Informatics Meeting, September 2014.
UK Renal Registry 16th Annual Report Figure 8.1. Trend in 1 year after 90 day incident patient survival by first modality, 2005–2011 cohort (adjusted to.
Summary of the 2012 ERA-EDTA Registry Annual Report Amsterdam, the Netherlands, 2014.
UK Renal Registry 17th Annual Report Figure 9.1. Median height z-scores for transplant patients
UK Renal Registry 16th Annual Report Figure Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2012.
UK Renal Registry 14th Annual Report Figure 8.1. Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2010.
UK Renal Registry 17th Annual Report Figure 8.1. Percentage of haemodialysis patients with phosphate within the range specified by the RA clinical audit.
UK Renal Registry 17th Annual Report Figure 3.1. Transplant prevalence rate per million population by age and gender on 31/12/2013.
Section 1: CKD Epidemiology. The Problem Chronic Kidney Disease is an epidemic worldwide –Growth 6-8% per annum of dialysis patients Accumulating data.
UKRR Annual Informatics Meeting, September 2013 Highlights from the 15 th Annual Report Rishi Pruthi Research Fellow UK Renal Registry.
UK Renal Registry 14th Annual Report Figure 3.1. Transplant prevalence rate per million population by age and gender on 31/12/2010.
UK Renal Registry 17th Annual Report Figure Percentage of patients waitlisted for a kidney transplant by renal centre, prior to or within two years.
Haemodialysis Vascular Access: Recent Trends From ANZDATA Dr Kevan Polkinghorne Monash Medical Centre ANZSN September 2007.
Information, Quality and Values Donal O’Donoghue National Clinical Director for Kidney Care Working for better kidney care UKRR and NHS Kidney Care Information.
Data completeness reporting Alex Hodsman, David Bull, Paul Dawson UK Renal Registry.
UK Renal Registry 17th Annual Report Figure 2.1. Prevalence rates per million population by age group and UK country on 31/12/2013.
UK Renal Registry 10th Annual Report 2007 Fig 3.1 Incident rates in the countries of the UK:
UK Renal Registry 9 th Annual Report 2006 Fig 13.1 ERF patients below 15 years of age, by year of data collection.
UK Renal Registry 9 th Annual Report 2006 Fig 11.1 UK transplantation prevalence rate per million population by age and gender on 31/12/2005.
UK Renal Registry 17th Annual Report Figure 1.1. RRT incidence rates in the countries of the UK 1990–2013.
UK Renal Registry 10th Annual Report 2007 Fig 8.1 Median haemoglobin for incident dialysis patients at start of dialysis treatment.
Survival after graft failure Dr Lynsey Webb Registrar UK Renal Registry UK Renal Registry 2011 Annual Audit Meeting.
UK Renal Registry 15th Annual Report Figure 6.1. Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2011.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 8: Pediatric ESRD.
UK Renal Registry 16th Annual Report Figure Percentage of haemodialysis patients with phosphate within the range specified by the RA clinical audit.
Summary of the 2013 ERA-EDTA Registry Annual Report Amsterdam, the Netherlands, 2015.
Highlights from the Registry year and Annual Report Professor Terry Feest Assistant Director UK Renal Registry UK Renal Registry 2011 Annual Audit Meeting.
Access to renal transplantation Chris Dudley UKRR/UKT Joint analysis.
UK Renal Registry 17th Annual Report Figure 4.1. RRT treatment used by prevalent paediatric patients
UK Renal Registry 10th Annual Report 2007 Fig 9.1 Annual change in percentage of dialysis patients with serum phosphate < 1.8mmol/L and ≥1.1 -≤1.8mmol/L.
UK Renal Registry 15th Annual Report Figure 7.1. Median height z-scores for transplant patients
UK Renal Registry 13th Annual Report
2016 Annual Data Report, Vol 2, ESRD, Ch 6
UK Renal Registry 18th Annual Report
ANZDATA Registry 39th Annual Report Chapter 13: End Stage Kidney Disease in Aotearoa/New Zealand Data to 31-Dec-2015.
Summary of the 2013 ERA-EDTA Registry Annual Report
Fig 7.1 Median URR achieved in each renal unit
UK Renal Registry 16th Annual Report
December 31st point prevalent counts by modality figure 3.1
UK Renal Registry 18th Annual Report
UK Renal Registry 9th Annual Report 2006
UK Renal Registry 10th Annual Report 2007
UK Renal Registry 19th Annual Report
CHAPTER 5 Paediatric Renal Replacement Therapy
CHAPTER 3 DEATHS Stephen McDonald 2012 Annual Report—35th Edition
UK Renal Registry 13th Annual Report
Fig 6.1 Frequency of ischaemic heart disease in incident patients
UK Renal Registry 16th Annual Report
UK Renal Registry 16th Annual Report
UK Renal Registry 14th Annual Report
UK Renal Registry 16th Annual Report
2013 Annual Report - 36th Edition
UK Renal Registry 15th Annual Report
UK Renal Registry 14th Annual Report
ANZDATA Registry 41st Annual Report Highlights of End Stage Kidney Disease in Australia and New Zealand Data to 31-Dec-2017.
UK Renal Registry 14th Annual Report
UK Renal Registry 16th Annual Report
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
UK Renal Registry 14th Annual Report
Fig 7.1 Median URR achieved in each centre, 2006
UK Renal Registry 10th Annual Report 2007
UK Renal Registry 12th Annual Report
UK Renal Registry 16th Annual Report
Presentation transcript:

Highlights from the Annual Report UK Renal Registry 2013 Annual Audit Meeting Dr Catriona Shaw Registrar, UK Renal Registry

UK Renal Registry 2013 Annual Audit Meeting

The Fifth Edition of the Clinical Practice Guidelines Module Blood-borne viruses Haemodialysis Vascular Access For Haemodialysis Peritoneal dialysis Peritoneal access Planning, initiation & withdrawal of RRT Assessment of the Potential Kidney Transplant Recipient Acute Kidney Injury Nutrition in CKD Anaemia in CKD Cardiovascular disease in CKD CKD-Mineral and Bone Disorders (CKD-MBD) Detection, Monitoring and Care of Patients with CKD Post-operative Care of the Kidney Transplant Recipient RA and ART Guideline on Water Treatment Facilities, Dialysis Water and Dialysis Fluid Quality for Haemodialysis and Related Therapies

DEMOGRAPHY RRT incidence rates between 1980 and 2011 UK Renal Registry 15th Annual Report

Figure 1.6. Median age of incident RRT patients by centre in 2011 White points indicate transplant centres

Population aged 65 and over, 2011 England and Wales local and unitary authorities

RRT incidence rates in the countries of the UK 1990–2011 UK Renal Registry 15th Annual Report

Figure International comparison of RRT incidence rates in 2010 Non UK data from USRDS

Prevalence rate of RRT patients per million population by age and gender on 31/12/2010

Growth in prevalent patients by treatment modality at the end of each year 1997–2011 UK Renal Registry 15th Annual Report MODALITY

UK Renal Registry 15th Annual Report RRT modality at 90 days (incident cohort 1/10/2010 to 30/09/2011)

UK Renal Registry 15th Annual Report Figure 2.6. Treatment modality in prevalent RRT patients on 31/12/2011

UK Renal Registry 15th Annual Report Figure 2.7. Treatment modality distribution by age in prevalent RRT patients on 31/12/2011

MULTISITE PERITONEAL DIALYSIS ACCESS CATHETER AUDIT

UK Renal Registry 15th Annual Report Figure 8.1. Age and gender of PD patients submitted to audit

UK Renal Registry 15th Annual Report Figure Access at first dialysis for centres reporting PD patients, by renal centre Based on 3,867 dialysis patients from centres that reported PD patients. Number of patients at each centre in brackets.

UK Renal Registry 15th Annual Report Figure Referral time from first being seen by renal physician to starting dialysis by type of first access Based on 3,545 patients from centres that reported PD patients, who had data on both referral time and type of first access. Total number of patients contributing data to the chart by access type included in x-axis labels (number with missing data in brackets).

UK Renal Registry 15th Annual Report Figure 9.4. Median time to wait listing for a kidney transplant, by renal centre (centres with <10 patients excluded) ACCESS TO TRANSPLANTATION

Starting dialysis in a non-transplanting centre was associated with being less likely to be registered for transplantation (adjusted OR 0.8, ) After adjustment for age, ethnicity, gender an PRD there were significant centre differences for the probability of being activated on the kidney transplant waiting list and the probability of receiving a renal transplant (all sources) ATTOM ACCESS TO TRANSPLANTATION

UK Renal Registry 15th Annual Report Figure 4.3. Primary renal disease percentage in incident and prevalent paediatric ERF patients in 2011 for whom a causative diagnosis was reported

UK Renal Registry 15th Annual Report Figure 4.4. Treatment modality at start of RRT by 5 year time period

OPPORTUNITIES CKD stage 5 patients to understand conservative and withdrawal issues AKI RADAR Specific need for research focused on improving outcomes in the elderly multi-morbid population (PROMs, PREMs)

VALID REPRODUCIBLE RELIABLE COMPLETE